APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Based Vaccines for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide-Based Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174023590330 December 2025197 pages

Choose your research edition.

Industry ResearchPeptide-Based Vaccines for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Based Vaccines for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide-Based Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Based Vaccines for Cancer Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Peptide-Based Vaccines for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide-Based Vaccines for Cancer include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide-Based Vaccines for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-Based Vaccines for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-Based Vaccines for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide-Based Vaccines for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide-Based Vaccines for Cancer Segment by Company

ACT

Almac

AmbioPharm

Anergis

Immatics

Immatics

Marker Therapeutics, Inc.

OncoPep

Sellas Life Sciences

Ultimovacs

Peptide-Based Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines

Recombinant Polypeptide Vaccine

Other

Peptide-Based Vaccines for Cancer Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Other

Peptide-Based Vaccines for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide-Based Vaccines for Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide-Based Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide-Based Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide-Based Vaccines for Cancer Industry Trends Table 2. Peptide-Based Vaccines for Cancer Industry Drivers Table 3. Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges Table 4. Peptide-Based Vaccines for Cancer Industry Restraints Table 5. Global Peptide-Based Vaccines for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide-Based Vaccines for Cancer Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Peptide-Based Vaccines for Cancer Sales Market Share by Manufacturers Table 9. Global Peptide-Based Vaccines for Cancer Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Peptide-Based Vaccines for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide-Based Vaccines for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide-Based Vaccines for Cancer Manufacturers, Product Type & Application Table 13. Global Peptide-Based Vaccines for Cancer Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide-Based Vaccines for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Synthetic Polypeptide Vaccines Table 17. Major Manufacturers of Recombinant Polypeptide Vaccine Table 18. Major Manufacturers of Other Table 19. Global Peptide-Based Vaccines for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 21. Global Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 22. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2026) Table 23. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2027-2032) Table 24. Global Peptide-Based Vaccines for Cancer Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (K Units) Table 26. Global Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (K Units) Table 27. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2026) Table 28. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Infectious Disease Prevention Table 30. Major Manufacturers of Cancer Immunotherapy Table 31. Major Manufacturers of Other Table 32. Global Peptide-Based Vaccines for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 34. Global Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 35. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2026) Table 36. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2027-2032) Table 37. Global Peptide-Based Vaccines for Cancer Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (K Units) Table 39. Global Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (K Units) Table 40. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2026) Table 41. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2027-2032) Table 42. Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026) & (K Units) Table 44. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2021-2026) Table 45. Global Peptide-Based Vaccines for Cancer Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Peptide-Based Vaccines for Cancer Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 49. North America Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 50. Europe Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 52. Europe Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 59. Global Peptide-Based Vaccines for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Peptide-Based Vaccines for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Peptide-Based Vaccines for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2021-2026) Table 63. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2027-2032) Table 64. ACT Company Information Table 65. ACT Business Overview Table 66. ACT Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. ACT Peptide-Based Vaccines for Cancer Product Portfolio Table 68. ACT Recent Development Table 69. Almac Company Information Table 70. Almac Business Overview Table 71. Almac Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Almac Peptide-Based Vaccines for Cancer Product Portfolio Table 73. Almac Recent Development Table 74. AmbioPharm Company Information Table 75. AmbioPharm Business Overview Table 76. AmbioPharm Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio Table 78. AmbioPharm Recent Development Table 79. Anergis Company Information Table 80. Anergis Business Overview Table 81. Anergis Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Anergis Peptide-Based Vaccines for Cancer Product Portfolio Table 83. Anergis Recent Development Table 84. Immatics Company Information Table 85. Immatics Business Overview Table 86. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 88. Immatics Recent Development Table 89. Immatics Company Information Table 90. Immatics Business Overview Table 91. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 93. Immatics Recent Development Table 94. Marker Therapeutics, Inc. Company Information Table 95. Marker Therapeutics, Inc. Business Overview Table 96. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio Table 98. Marker Therapeutics, Inc. Recent Development Table 99. OncoPep Company Information Table 100. OncoPep Business Overview Table 101. OncoPep Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. OncoPep Peptide-Based Vaccines for Cancer Product Portfolio Table 103. OncoPep Recent Development Table 104. Sellas Life Sciences Company Information Table 105. Sellas Life Sciences Business Overview Table 106. Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio Table 108. Sellas Life Sciences Recent Development Table 109. Ultimovacs Company Information Table 110. Ultimovacs Business Overview Table 111. Ultimovacs Peptide-Based Vaccines for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio Table 113. Ultimovacs Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Peptide-Based Vaccines for Cancer Distributors List Table 117. Peptide-Based Vaccines for Cancer Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Peptide-Based Vaccines for Cancer Product Image Figure 2. Global Peptide-Based Vaccines for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Based Vaccines for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide-Based Vaccines for Cancer Sales (2021-2032) & (K Units) Figure 5. Global Peptide-Based Vaccines for Cancer Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide-Based Vaccines for Cancer Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Synthetic Polypeptide Vaccines Image Figure 9. Recombinant Polypeptide Vaccine Image Figure 10. Other Image Figure 11. Global Peptide-Based Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Peptide-Based Vaccines for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2032) Figure 14. Global Peptide-Based Vaccines for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Peptide-Based Vaccines for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2032) Figure 17. Infectious Disease Prevention Image Figure 18. Cancer Immunotherapy Image Figure 19. Other Image Figure 20. Global Peptide-Based Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Peptide-Based Vaccines for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2032) Figure 23. Global Peptide-Based Vaccines for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Peptide-Based Vaccines for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2032) Figure 26. North America Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2032) Figure 28. U.S. Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2032) Figure 33. Germany Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2032) Figure 40. China Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2032) Figure 48. Brazil Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Peptide-Based Vaccines for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Peptide-Based Vaccines for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Figure 59. North America Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Figure 61. Europe Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Peptide-Based Vaccines for Cancer Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Peptide-Based Vaccines for Cancer Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Synthetic Polypeptide Vaccines
  • Recombinant Polypeptide Vaccine
  • Other
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Other
Companies covered
  • ACT
  • Almac
  • AmbioPharm
  • Anergis
  • Immatics
  • Immatics
  • Marker Therapeutics, Inc.
  • OncoPep
  • Sellas Life Sciences
  • Ultimovacs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide-Based Vaccines for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide-Based Vaccines for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide-Based Vaccines for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide-Based Vaccines for Cancer Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide-Based Vaccines for Cancer Market Dynamics
  1. 2.1 Peptide-Based Vaccines for Cancer Industry Trends
  2. 2.2 Peptide-Based Vaccines for Cancer Industry Drivers
  3. 2.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
  4. 2.4 Peptide-Based Vaccines for Cancer Industry Restraints
3 Peptide-Based Vaccines for Cancer Market by Manufacturers
  1. 3.1 Global Peptide-Based Vaccines for Cancer Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide-Based Vaccines for Cancer Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide-Based Vaccines for Cancer Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide-Based Vaccines for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide-Based Vaccines for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide-Based Vaccines for Cancer Manufacturers, Product Type & Application
  7. 3.7 Global Peptide-Based Vaccines for Cancer Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide-Based Vaccines for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide-Based Vaccines for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide-Based Vaccines for Cancer Tier 1, Tier 2, and Tier 3
4 Peptide-Based Vaccines for Cancer Market by Type
  1. 4.1 Peptide-Based Vaccines for Cancer Type Introduction
  2. 4.1.1 Synthetic Polypeptide Vaccines
  3. 4.1.2 Recombinant Polypeptide Vaccine
  4. 4.1.3 Other
  5. 4.2 Global Peptide-Based Vaccines for Cancer Sales by Type
  6. 4.2.1 Global Peptide-Based Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  8. 4.2.3 Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2032)
  9. 4.3 Global Peptide-Based Vaccines for Cancer Revenue by Type
  10. 4.3.1 Global Peptide-Based Vaccines for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  12. 4.3.3 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2032)
5 Peptide-Based Vaccines for Cancer Market by Application
  1. 5.1 Peptide-Based Vaccines for Cancer Application Introduction
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Other
  5. 5.2 Global Peptide-Based Vaccines for Cancer Sales by Application
  6. 5.2.1 Global Peptide-Based Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 5.2.3 Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peptide-Based Vaccines for Cancer Revenue by Application
  10. 5.3.1 Global Peptide-Based Vaccines for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  12. 5.3.3 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2032)
6 Global Peptide-Based Vaccines for Cancer Sales by Region
  1. 6.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide-Based Vaccines for Cancer Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide-Based Vaccines for Cancer Revenue by Region
  1. 7.1 Global Peptide-Based Vaccines for Cancer Revenue by Region
  2. 7.1.1 Global Peptide-Based Vaccines for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide-Based Vaccines for Cancer Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide-Based Vaccines for Cancer Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide-Based Vaccines for Cancer Revenue (2021-2032)
  8. 7.2.2 North America Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide-Based Vaccines for Cancer Revenue (2021-2032)
  11. 7.3.2 Europe Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide-Based Vaccines for Cancer Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide-Based Vaccines for Cancer Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide-Based Vaccines for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ACT
  2. 8.1.1 ACT Company Information
  3. 8.1.2 ACT Business Overview
  4. 8.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
  6. 8.1.5 ACT Recent Developments
  7. 8.2 Almac
  8. 8.2.1 Almac Company Information
  9. 8.2.2 Almac Business Overview
  10. 8.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
  12. 8.2.5 Almac Recent Developments
  13. 8.3 AmbioPharm
  14. 8.3.1 AmbioPharm Company Information
  15. 8.3.2 AmbioPharm Business Overview
  16. 8.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
  18. 8.3.5 AmbioPharm Recent Developments
  19. 8.4 Anergis
  20. 8.4.1 Anergis Company Information
  21. 8.4.2 Anergis Business Overview
  22. 8.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
  24. 8.4.5 Anergis Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Immatics
  32. 8.6.1 Immatics Company Information
  33. 8.6.2 Immatics Business Overview
  34. 8.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  36. 8.6.5 Immatics Recent Developments
  37. 8.7 Marker Therapeutics, Inc.
  38. 8.7.1 Marker Therapeutics, Inc. Company Information
  39. 8.7.2 Marker Therapeutics, Inc. Business Overview
  40. 8.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
  42. 8.7.5 Marker Therapeutics, Inc. Recent Developments
  43. 8.8 OncoPep
  44. 8.8.1 OncoPep Company Information
  45. 8.8.2 OncoPep Business Overview
  46. 8.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
  48. 8.8.5 OncoPep Recent Developments
  49. 8.9 Sellas Life Sciences
  50. 8.9.1 Sellas Life Sciences Company Information
  51. 8.9.2 Sellas Life Sciences Business Overview
  52. 8.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
  54. 8.9.5 Sellas Life Sciences Recent Developments
  55. 8.10 Ultimovacs
  56. 8.10.1 Ultimovacs Company Information
  57. 8.10.2 Ultimovacs Business Overview
  58. 8.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
  60. 8.10.5 Ultimovacs Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
  2. 9.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide-Based Vaccines for Cancer Production Mode & Process
  6. 9.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide-Based Vaccines for Cancer Distributors
  9. 9.2.3 Peptide-Based Vaccines for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst